 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

iCAD partners with RAD-AID to advance breast cancer detection

iCAD implements ProFound AI Detection to improve mammography reading and breast cancer detection in low-resource institutions and medically underserved communitiesNASHUA, N.H., April 03, 2024...

iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

ProFound Cloud redefines accessibility to critical insights, empowering radiologists in early breast cancer detectionNASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a...

iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

Newly released capabilities -- limiting the number of marks on a 3D view, color-coding lesion marks, and color-coding the ProFound Scorecard -- enhance radiologists' interpretability and...

iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

Q4 2023 ICAD Inc Earnings Call Transcript

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA, N.H...

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

Clinical evidence demonstrates ProFound Detection's AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives Findings reveal substantially...

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Dr. Hricak offers extensive experience in radiology, real-world application of AI-enabled imaging solutions, research, and global healthcare perspectivesNASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE...

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.c )

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NASHUA, N.H., Feb. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...

iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Volume (M)	143,053.00
52-Wk High	$3.97
52-Wk Low	$1.05

ICAD Icad Inc

About

Feed

News

Sentiment

Earnings

Fundamentals